ORIGINAL RESEARCH

## RETRACTED ARTICLE: MicroRNA-155-3p promotes breast cancer progression through down-regulating CADM1

This article was published in the following Dove Press journal: OncoTargets and Therapy

Guochao Zhang Lele Zhong Hao Luo Shibing Wang

Department of Breast and Thyroid Surgery, Affiliated Jining No. I People's Hospital of Jining Medical University, Jining Medical University, Jining, Shandong 272011, People's Republic of China



Correspondence: Shibing Wang Department of Breast and Thyroid Surgery, Jining No. I People's Hospital, Jining Medical University. No. 6 Jiankang Road, Jining, Shandong 272011, People's Republic of China Email Wangshibing689@163.com



**Background/purpose:** Cell adhesion molecule 1 (CADM, o functions as ortumor suppressor and has been identified to be frequently inactivated in creast canor, and closely associated with patients' poor prognosis and advanced TNM stage Housever, the mechanisms underlying CADM1 in breast cancer programion remains incompletely clear. miR-155, a predicted modulator of CADM1 was reported to the acceptores of in breast cancer, and its high expression level was closely related to the malign at procession of breast cancer. The present study aimed to explore whether min 155-3p could codulate CADM1 expression and then involved in the progression of breast cancer.

**Methods:** The expression particulars of miR-155-3pt obreast cancer tissues and cell lines were determined by RT-PCR tech ology. The relationship between CADM1 and miR-155-3p were determined by the luciferast gene reporter and Western Blot (WB) assays. Cell proliferation, apoptosis rates and tumorigenesis were chermined by CCK-8, flow cytometry and in vivo xenotransplanation cherminents, repeated.

**Results:** miR-15.12 p was a conclused in breast cancer tissues and cells when compared to the adjacent normal sciels and normal breast MCF 10A cells. The mRNA and protein levels of C 20M1 powed c posite expression patterns to that of miR-155-3p expression detected, as miR-156.3p could regatively regulate CADM1 expression in breast cancer MCF-7 cells. Moreover gain-or-maction assay showed that overexpression of miR-155-3p promoted cell prolifer tion, tumorigenesis and repressed cell apoptosis, but these effects were all significantly implied when the cells were simultaneously transfected with OE-CADM1, the prexpressing vector of CADM1.

**Conclusion:** This study revealed that miR-155-3p could accelerate the progression of breast cancer via down-regulation of CADM1 expression.

Keywords: miR-155-3p, CADM1, breast cancer

#### Introduction

Breast cancer is the second most frequent tumor among all kinds of cancers and accounts for the leading type of tumor in women, with an increasing incidence every year worldwide.<sup>1</sup> Although advances in oncological therapy have improved the survival rates of breast cancer patients, a large number of patients still suffer postsurgical pain, as well as tumor progression and metastasis.<sup>2</sup> Overall, the prognosis for patients with breast cancer still remains dim.<sup>3</sup> Therefore, new therapeutic strategies are urgently needed to be explored to shed light on molecular mechanisms underlying breast cancer progression.

Cell adhesion molecule 1 (CADM1), also known as TSLC1 (tumor suppressor in lung cancer 1), was first found to function as a tumor suppressor in non-small

© 2019 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission form Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial uses of this work, is paragraphs 2.2 and 5 of our Terms (https://tww.dovepress.com/terms.php). cell lung cancer cells in 2001.<sup>4</sup> CADM genes exert a protect role against malignant conversion and metastasis through maintenanceof epithelia. CADM1 is frequently lost in invasive lung adenocarcinoma lesions when compared with those non-invasive lung adenocarcinoma lesions.<sup>5</sup> In recent years, accumulated evidences have confirmed that CADM1 is always inactivated in breast cancer, and its inactivation closely associated with patients' poor prognosis and advanced progression.<sup>6-8</sup> For example, a study published by Saito et al<sup>8</sup> reported that 76.9% (160/ 208) of primary invasive breast cancer tissues showed CADM1 negative expression, and lack of CADM1 expression in these cases was associated with advanced tumor stage, suggesting a vital role of CADM1 plays in breast cancer. However, the mechanisms underlying CADM1 in breast cancer still remains largely unclear.

MicroRNAs (miRNAs) are a series of small singlestranded non protein coding RNAs (20-25 nucleotides) and serve as primary negative regulators of 60% of all human protein coding genes at post-transcriptional level.9-11 MiRNAs are reported to be involved in multiple physiological processes, such as cell cycle, growth, apoptosis, differentiation and metabolism, and can function as both tume suppressors and oncogenes.<sup>12</sup> MiR-155 was significant elevated in breast cancer tissues compared to normal adjoining tissues and the high levels of it displayed rtical Sh association with the positive lymph node preastasis atus, particularly for triple negative breast can aems Conformably, Zheng et al<sup>14</sup> found the miR-155 pression was significantly higher in breast and tumor tisse than that in the matched non-tumor ssues, and high expression levels closely related to mph node positivy, advanced clinical TNM stage an higher oliferation index. In addikdown comiR-155 obviously tion, they also found that and huc cell viability in breast promoted cell opto. cancer HS5 of cells dowever, he underlying mechanism of miR-155 in the cancer is still unknown. Bioinformatics analysis shows the CADM1 is a predicted target of miR-155-3p, but whether ADM1 is under a negative regulation of miR-155-3p in breast cancer remains unknown.

The present study aimed to explore the expression patterns of miR-155-3p and CADM1 in breast cancer, and investigate the relationship between miR-155-3p and CADM1, with the ultimate goal of determination that whether miR-155-3p promotes the progression of breast cancer through down-regulating CADM1 expression.

### Materials and methods Patients and samples obtain

One hundred and twenty-eight paired fresh cancer tissue samples and normal r tissue samples were obtained from patients with breast cancer in Jining No.1 People's Hospital between January 2012 and December 2016. All patients were not subjected to preoperative radiotherapy and/or chemotherapy and all provided written informed consent. The diagnosis and histological grade of each breast cancer were independently determined by two pathologists on the base of WHO classification.<sup>15</sup> Experime .o 11 ving human samples were performed in acceptance with a Helsinki Declaration and were approved by the ethical co mittee of Jining Medical University

#### Cell culture

, MDA-MB-231 and Breast cance lines M F HCC1937, as well normal breast cell line MCF 10A were attend from merican Type Culture Collection C, Manassas, VA, USA). MCF-7 cells were cultured in (AT Eag 's Minimun Essential Medium (No. 30-2003; ATCC, ns, VA, SA), supplemented with 0.01 mg/mL Mana uman recombinant insulin and 10% fetal bovine serum s, bco, MA, USA). HCC1937 cells were grown in  $(\mathbf{F})$ ATCC-formulated RPMI-1640 Medium (No. 30-2001) fillng with 10% FBS. MDA-MB-231 cells were cultured in ATCC-formulated Leibovitz's L-15 Medium (No. 30-2008) filling with 10% FBS. MCF 10A were cultured in MEGM Kit (No. CC-3150; Lonza/Clonetics Corporation, CA, USA) with 100 ng/mL cholera toxin (No. C8052; Sigma, MA, USA). All cells were kept in a humidified atmosphere at 37 °C with 5% CO<sub>2</sub>.

#### Cell transfection

Small interfering RNAs (siRNAs) (si-CADM1; No. SR308445, OriGene, Beijing, China) and short hairpin RNA (shRNA) (sh-CADM1; No. TL312210, OriGene) targeting human CADM1 gene were used to down-regulate CADM1 expression. The overexpressing plasmid of CADM1 (OE-CADM1; No. SC115048, OriGene) was used to up-regulate CADM1 expression. To silence and overexpress miR-155-3p, the mimics and inhibitors of miR-155-3p were synthesized by GenePharma (Shanghai, China). Lipofectamine 2000 transfection reagent (Invitrogen, CA, USA) was used for cell transient transfection, referring to manufacturer's instruction.

Mimics-miR-155-3p: 5'-CUCCUACAUAUUAGCAUU AACA-3',

Mimic-NC: 5'-UUCUCCGAACGUGUCACGUTT-3'; Inhibitors-miR-155-3p: 5'-UGUUAAUGCUAAUAUG UAGGAG-3',

Inhibitor-NC: 5'-CAGUACUUUUGUGUAGUACA A-3].

## Total RNA isolation and real-time PCR (RT-PCR)

Trizol reagent (Invitrogen) was used to extract the total RNA from breast cancer tissues, adjacent non-tumor tissues and cell lines, conforming to the producer's recommendations. Following reverse transcription with the TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, CA, USA), miR-155-3p and U6 expression patterns were detected by RT-PCR with TaqMan® MicroRNA Assays (Applied Biosystems) in accordance with the manufacturer's directions. The expression patterns of CADM1 and GAPDH were measured with QuantiTect Reverse Transcription Kit and RT-PCR Kit (Qiagen, Beijing noble Ryder Technology Co. LTD, Beijing, China). The mRNA expressions vere assessed by relative quantification using the method. U6 and GAPDH expression levels were use to normalize miR-155-3p and CADM1, r pec. ely. primers used for this study were listed is follow

GAPDH-forward (F): 5'-GAGAAO CT agoe. A TTT-3',

GAPDH-reverse (R): 5' AC GATGGCA GGACTG TGG-3';

CADM1-F: 5'-CCLCAGGTGATGC CAGAAT-3', CADM1-R: 5' TCCTC GGGGGGATCGGTAT-3'; U6-F: 5'-CTCGC TLGGCAC ACA-3', U6-R: 5' AALGCT ACCLATTTGCGT-3'.

### Wester Jot analysis (WB)

Total proteins, from tissue samples and cells were obtained with RIPA lysis suffer (Beyotime Biotechnology, Jiangsu, China). After centrifugation, proteins in the supernatant were degenerated at 100 °C for 10min and quantified using a BCA kit (ThermoFisher Scientific, MA, USA). Then, the proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidine difluoride filter (PVDF) membrane (Millipore, MA, USA). After blocking with 10% nonfat milk in PBS diluted with TBST (Tris Buffered Saline Tween-20), the membranes were probed with the following antibodies, including CADM1 (No. C2121, Sigma-Aldrich, MO, USA), cleaved caspase3 (No. 9664, Cell Signaling Technology, MA, USA), caspase3 (No. 9662, Cell Signaling Technology), Bax (No. 2774, Cell Signaling Technology), Bcl-2 (No. 15071, Cell Signaling Technology) and GAPDH (Santa Cruz Biotechnology, CA, USA), followed by HRP-linked secondary antibodies (Thermo Fisher Scientific). The western signaling were enhanced by ECL detection (Millipore) and detected by Gel imaging system (Thermo Fisher Scientific). The western bands are quartified by ImageJ software after background surfaction.

## Cell Counting Kit-8 ssay CK-8)

Cell proliferation we detected using Cell Counting Kit-8 assay (CCK c). Briefly, different transfected MCF-7 cells (mimic-NC, clinics, inhibitor-NC, inhibitors, inhibitor-NC + si-CADM r, while the si-CADM1, mimic-NC + OE-CADM1, mimics + CE-CADM1) were plated in a 96-well late at a density of 200 cells/well. After 1, 2, 3, 4 and 5 days if the treatment, the medium was replaced with 10  $\mu$ L CCK-8 repeated and 0  $\mu$ L fresh culture medium for another 3 h, respectively. Light absorbance at 450 nm was measured with a neoplate reader.

#### Flow cytometry

The effects of miR-155-3p/CADM1 axis on the apoptosis of MCF-7 cells was assessed by flow cytometry with Annexin V (FITC)/PI Apoptosis Detection Kits (BD Biosciences, USA) according to the manufacturer's instructions. After 48 h of cell transfections, MCF-7 cells were collected and washed with PBS, followed by incubation with the Annexin V-FITC and PI solution. The fluorescent signal was measured by flow cytometry within 1 h of the staining. FITC-/PI-quadrant represents living cells, FITC+/PI- represents early apoptotic cells and FITC+/PI+ represents late apoptotic cells.

#### Luciferase report assay

The 3' UTR sequence of CADM1 mRNA (wild type, WT) and the mutated sequence within the binding sites among miR-155-3p and CADM1 (mutated type, MT) were inserted into the pmiR-GLO dual-luciferase vector (Promega, WI, USA). Subsequently, cells were co-transfected with mimics or mimic-NC together with WT or MT. After 48 h of the transfections, cells were collected and submitted to a dual-luciferase reporter gene assay system

(Promega). Renilla luciferase activity was used as an internal control.

## In vivo model establishment and treatment

All procedures referring to animal experiments in this study were performed in accordance with the principles and procedures of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the ethical committee of Jining Medical University. Four-week-old male BALB/c nude mice (20–22 g) were purchased from Shanghai SLAC Laboratory Animal Co, Ltd. (Shanghai, China). The mice were fed in separate cages in a pathogen-free environment, under a 12 h-light/dark cycle.

MCF-7 cells transfected with control, mimics, mimic + CADM1, inhibitors and inhibitor + sh-CADM1 were resuspended with 200  $\mu$ L PBS and then subcutaneously injected into BALB/c mice (n=10 for each group). The mice were euthanized 21 days post-injection. Then the tumors were took out and the weights were recorded.

#### **Statistics**

All data are presented as mean  $\pm$  the standard deviation (SD). Differences between groups were exchanged by SPSS 17.0 software. Specifically, student *i t*-test or oneway ANOVA test was executed to compare the differences between two groups or more. A log mark with Kap on-Meier survival analysis was performed to assure the overal survival (OS) of breast cancer patients with high low expression of miR-155-3p. A *P*-value<0.05 was considered statistically significant.

#### Results

# miR-155-3p is highly expressed in breast cancer tissues and cells

To explore the effects of miR-155-3p on the occurrence and development of breast cancer, we first determined its expression levels in breast cancer tissues and cells through RT-PCR. The results showed that miR-155-3p had a higher expression pattern i cer tissues oreast C than that of the adjacent non-tupor tissues (A rure 1A). Likewise, miR-155-3p bviously was oress increased in breast ncer cell HCC1937, es MDA-MD-231 and MF-7) compared to the normal agure 1, and we chose breast MCF 10/ cells further stu ese results suggested MCF-7 cells overexpressed in breast cancer, that miR-15-3p and it t function an oncogene in breast cancer prog ession.

## High expression of miR-155-3p is closely toociated with patients' advanced rogression and poor prognosis

Then, we analyzed the association between miR-155-3p pression levels and breast cancer patients' progression and prognosis. Eighty-five breast cancer patients with miR-155-3p high expression and forty-three patients with miR-155-3p low expression were chosen for our study. From the statistical analysis results listed in Table 1, it




Figure I miR-155-3p expression was elevated in breast cancer tissues and cells. (A) RT-PCR was performed to evaluate miR-155-3p expression in 40 matched breast cancer tissues and its adjacent normal tissues (n=40; P<0.05, tumor group vs control group). (B) RT-PCR analysis of the mRNA level of miR-155-3p in normal breast cell line MCF 10A and breast cancer HCC1973, MCF-7 and MDA-MB-231 cell lines (n=3; \*\*\*P<0.001, HCC1973/MCF-7/MDA-MB-231 group vs MCF 10A group). (C) OS was used to evaluate the association between miR-155-3p expression levels with breast cancer patients' prognosis.

Features	Total (n)	High expression	Low expression	P-values
Age (years)				0.114
≤50	56	33	23	
>50	72	52	20	
Tumor size (cm)				0.266
≤3.0	48	29	19	
>3.0	80	56	24	
LN metastasis				0.027
Negative	53	25	28	
Positive	75	50	25	
PR expression				0.663
Negative	63	43	20	
Positive	65	42	23	
ER expression				0.475
Negative	51	32	19	
Positive	77	53	24	
HER-2 expression				0.461
Negative	45	28	17	
Positive	83	57	26	
TNM				0.001
1-11	47	21	26	
III-I∨	81	64	17	

Abbreviations: LN, lymph node; ER, estrogen eceptor; h rogesterone receptor; EPR-2, epidermal growth factor receptor

indicated that high expression of miRe 55-3p was closely associated with the righ incidence of EN (lymph node) metastasis (P=0.02 cando avanced TNM stage (P=0.001). Moreover, OS rescale ated as the time from diagnosis to the date or death or last context and was used to evaluate the association later on miR-155-3p expression levels and patients' promosis. The results revealed that patients with high expression of miR-155-3p always showed a shorter OS than that in patients with low expression of miR-155-3p (Figure 1C).

## Overexpression of miR-155-3p promotes cell proliferation and inhibits cell apoptosis in breast cancer

Next, we explored the function of miR-155-3p in the proliferation and apoptosis of MCF-7 cells. Up-regulation


of miR-155-3p viamiR-155-3p mimic transfection obviously increased the expression of miR-155-3p, and vice versa (Figure 2A). Compared with the mimic-NC (negative control) group, MCF-7 cells with miR-155-3p mimic transfection showed a significant increase in cell proliferation, and knockdown of miR-155-3p with inhibitors transfection induced an opposite result (Figure 2B). Moreover, up-regulation of miR-155-3p significantly repressed cell apoptosis from 11.43% to 5.32% (total early and late apoptosis), and down-regulation of miR-155-3p apparently promoted cell protosis from 10.95% to17.64% (total early and lat apoptos, as compared with that in the control group (Figure 2C) nd D). These data revealed that miR 5-3p ved as oncogene in the progression of be ast cancer.

## miR-155-7p negatively modulates CADM repression of breast cancer

Moreover, we expred the underlying mechanism of miR--sp in breast cer development and determined hether CAPM1 took part in this process. First, we assessed e expression level of CADM1 in breast cancer tissues and RT-PCR and WB analysis results showed that the mRNA and protein expression levels of CADM1 were read in breast cancer tissues when compared to the adjacent normal tissues (Figure 3A and B). Similarly, the mRNA and protein levels of CADM1 in breast MCF-7, HCC1937 and MDA-MB-231 cells were obviously lower than that in MCF 10A, a normal breast cell line (Figure 3C and D). Upregulation of miR-155-3p significantly decreased CADM1 expression and down-regulation of miR-155-3p increased CADM1 expression not only in mRNA level but also in protein level (Figure 3E and F). Furthermore, luciferase report assay showed that the luciferase activity of CADM1 WT vector was obviously decreased when MCF-7 cells were transfected with miR-155-3p mimics as compared with mimic-NC group, whereas this effect was abrogated when the binding sites were mutated (Figure 3G). Taken together, these results showed that CADM1 under the negative regulation of miR-155-3p was lowly expression in breast cancer tissues and cells.

## miR-155-3p accelerates the progression of breast cancer through down-regulation of CADM1 expression

To explore whether CADM1 takes part in miR-155-3pmediated acceleration in breast cancer progression,



their

**Figure 2** Up-regulation of miR-155-3p promoted cell proliferation and inhib to efficiencies after MCF-7 cells were transfected with miR-155-3p mimic, inhibitor or their controls. (**C–D**) Flow cytom were treated with miR-155-3p mimic, inhibitor or their controls (right lower quadre \*\*P<0.01, \*\*\*P<0.001, mimic group vs mimic-NC group; #P<0.05


CADM1 overexpressing plasmid s were recruited. siRNA-1 targeting CAD gene showe the best knockdown efficiency among the three iRNAs, and OE-CADM1 transfection significantly inclused CADM1 o the control group (Figure 4A expression as compared and B). Knockdown miR\_5-3p obviously enhanced MCF-7 cell proliferation, we reas CAL M1 knockdown proni -155-3p inhibitor role in moted cell gro th and mpaire (Figure 4C). Cell apoptosis rate was proliferation unhibiti significantly ased when miR-155-3p was knocked down, whereas CMM1 downregulation induced an opposite result and weakened miR-155-3p inhibitor-mediated cell apoptosis promotion (Figure 4E). In addition, si-CADM1 transfection significantly rescued miR-155-3p inhibitorsmediated increases in the relative expression levels of cleaved caspases3/caspase3 and Bax/Bcl-2 (Figure 4G and I). Consistently, both proliferation promotion and apoptosis repression roles of miR-155-3p mimics were terminated when the cells were transfected with miR-155-3p mimic and OE-CADM1 at the same time (Figure 4D and F), as well as

tapoptosis in a cancer MCF-7 cells. (A) RT-PCR analysis of the transfected in a concerned by (B) CCK-8 analysis the proliferation of MCF-78 cells after the cells were with annual (FITC)/PI staining used to determine cell apoptosis after MCF-7 cells present early apoptosis cells and right upper represent late apoptosis cells). (n=3, group vs inhibitor-NC group).

the reductions of the relative expression of cleaved caspases3/caspase3 (Figure 4H) and Bax/Bcl-2 (Figure 4J). Moreover, up-regulation of miR-155-3p promoted cell tumorigenesis and down-regulation of it repressed tumorigenesis, and the roles of miR-155-3p up-regulation or downregulation played in tumorigenesis were significantly abolished when CADM1 and miR-155-3p were simultaneously up-regulated or down-regulated (Figure 5). Taken together, these data demonstrated that miR-155-3p promoted breast cancer progression via down-regulation of CADM1 expression.

#### Discussion

CADM1 has been identified as a tumor suppressor in breast cancer, and its low expression level closely associates with patients' advanced clinical and pathological characteristics and poor prognosis,<sup>6–8,16</sup> suggesting that CADM1 might be regarded as an effective target for breast cancer treatment. CADM1 is a target of many miRNAs, such as miR-1246,<sup>17</sup>




in breast A-B) RT-PCR and WB analysis of the mRNA and protein levels of CADMI in 30 paired Figure 3 miR-155-3p down-regulated CADM1 express ncer cells the repr breast cancer tissues and adjacent non-tumor tissues ve WB figur vas shown in 3B (n=30; \*P<0.05, \*\*P<0.01, tumor group vs control group). (**C–D**) RT-PCR and WB analysis of the mRNA and protein vels AD er HCC1973, MCF-7 and MDA-MB-231 cell lines (n=3; \*\*P<0.01, \*\*\*P<0.001, HCC1973/ n br (E-F) RT and WB analysis of the mRNA and protein levels of CADMI after MCF-7 cells were transfected with miR-MCF-7/MDA-MB-231 group vs MCF 10A group 3, \*\*\*P<0.001, ics group vs mimic-NC group; ###P<0.001, inhibitors group vs inhibitor-NC group). (G) The luciferase 155-3p mimics, inhibitors or their controls R-155-3p MT (mutation) or WT (wild type) (n=3, \*P<0.05, mimics groups vs mimic-NC group; #P< activity of CADML promoter after trans 10 MCF-7 cells wi 0.05, inhibitors group vs inhibitor-NC soup).

4<sup>20</sup> and miR-375.<sup>20</sup> The premiR-10b.<sup>18</sup> miR-2 / miR/ sent study explored ationship between CADM1 and miR-155-3 Th xpres. ns miR-155-3p and CADM1 estigated in 40 makined primary breast cancer tiswere in ponding normal tissues. High expression of sues and s observed in breast cancer tissues while low miR-155-3p expression of CDM1 was observed, which indicated that there might be a possible interaction between miR-155-3p and CADM1 in breast cancer. It was further confirmed in the following WB analysis and luciferase report assay, which showed that miR-155-3p negatively regulated CADM1 expression in breast cancer MCF-7 cells.

Multiple clinical and pathological factors are used to classify breast cancer patients so as to evaluate patients' prognosis and determine the best treatment options, including age, tumor size, LN metastasis, lymphovascular invasion, nuclear grade, expression pattern of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2).<sup>6,21,22</sup> In the current study, we found that high expression level of miR-155-3p showed a positive association with patients' LN metastasis (P=0.001) and advanced TNM stage, but had no significant influence in the expression levels of PR, ER and HER-2. In addition, the prognosis analysis indicated that patients with miR-155-3p high expression had a shorter OS than that of patients with miR-155-3p low expression. Our findings were consistent with previous studies.<sup>14,23,24</sup>


Zuo et al<sup>25</sup> reported that inhibition of miR-155 could significantly repress proliferation of breast cancer MDA-



CADMI group vs OE-NC group). ( ess cell proliferation after MCF-7 cells were transfected with inhibitor-NC + si-NC, inhibitors + si-NC, inhibitor-NC + si-CADMI and inh ors + si-GADMI, respectively (n=3, \*P<0.05, \*\*\*P<0.001, inhibitors + si-NC group or inhibitor-NC + si-CADMI group vs inhibitor-NC + si-NC group; ##P<0.01 ibitor +  $\mathcal{I}$ ADMI group vs inhibitors + si-NC group). (**D**) CCK-8 was used to assess cell proliferation after MCF-7 cells were cs + OE-NC, mimic-NC + OE-CADMI and mimics + OE-CADMI (n=3, \*P<0.05, \*\*\*P<0.001, mimics + OE-NC group or transfected with mimic-NC + O IC, mimic-NC + OE-CADML group vs c-NC + O C group; ##P<0.01, mimics + OE-CADMI group vs mimics + OE-NC group). (E) Flow cytometry was used to sfected with inhibitor-NC + si-NC, inhibitors + si-NC, inhibitor-NC + si-CADMI and inhibitors + si-CADMI, assess cell apoptosis F-7 ce ere t respectively (n=3, <0.05. ir itors + roup or inhibitor-NC + si-CADM1group vs inhibitor-NC + si-NC group; <sup>#</sup>P<0.05, inhibitor + si-CADM1 group vs inhibitors + sigroup). (F ow cytometry was used to assess cell apoptosis after MCF-7 cells were transfected with mimic-NC + OE-NC, mimics + OE-NC, mimic-NC + OE-CAD ▶MI (n=3, \*\*P<0.01, mimics + OE-NC group or mimic-NC + OE-CADMI group vs mimic-NC + OE-NC group; ##P<0.01,</p> nd r up vs mimics + OE-NC group). (G-J) WB technology was applied to detect the expressions of cleaved caspase3, total caspase3, Bcl-2 and Bax mimics + OE-CAD with different vectors (n=3, \*P<0.05,  $^{#}P<0.05$ ). after cells were transf

MB-231 cells in vivo and in vitro, and miR-155 expression levels strongly correlated with cells' stem-like properties. Wang et al<sup>26</sup> revealed that up-regulation of miR-155-5p promoted cell proliferation and reduced bufalin-induced apoptosis in triple-negative breast cancer cells. In this study, we revealed that up-regulation of miR-155-3p significantly promoted the proliferation and tumorigenesis and repressed apoptosis of breast cancer MCF-7 cells, but these effects were all broke up when CADM1 was over-expressed, indicating that miR-155-3p promoted the progression of breast cancer in a CADM1-inexistent manner.

However, there are several limitations in our study. CADM1/TSLC1, as a membrane-spanning glycoprotein pertaining to the superfamily of immunoglobulin cell adhesion molecules, has been proved that its depletion accounts for a



**Figure 5** In vivo xenograft assay analysis of the tumor-forming potential. MCF-7 cells were stably transfected control, miR-155-3 minics,  $P_{155-3p}$  minics + OE-CADM1, miR-155-3 minibitors and miR-155-3 minibitors + sh-CADM1, then the cells were subcutaneously injected into the cells of mice (10/group). (\*\*P<0.01, \*\*\*P<0.01, mimic/inhibitor group vs control group; ##P<0.01, mimics+CADM1 group vs mimics group; +\*P<0.01, inhibitors + value (\*\*P<0.01, mimics+CADM1 group vs mimics).

main reason for cancer cell invasion and metastasis.<sup>27,28</sup> Besides, miR-155 was reported to induce drug resistance in breast cancer.<sup>29</sup> However, whether miR-155-3p can enhance cell migration and invasion, as well as induce drug resistance through down-regulating CADM1 expression in breast cancer is not illuminated in the current study. We intend to reveal it thoroughly in the further study.

In conclusion, this study reveals a strong correlation between miR-155-3p high expression and breast cancer patients' LN metastasis and TNM stage. We first it that overexpression of miR-155-3p negatively reg ates CADM1 expression and then promotes the adve ced prog sion of breast cancer. MiR-155-3p/CADM axis n pht ser as a novel biomarker to predict the programsion ar mosi of breast cancer, as well as a potent the rapeu get for breast cancer treatment.

#### Disclosure

The authors have declared that no competing interest exists in this work.

## References

- 1. Sieger, Naisher and Lamal A. Cancer statistics, 2013. *CA Cancer J Clin.* 2. (1):11–30. doi:10.3322/caac.21166
- Krop IE, Kim SB, Gonzalez-Martin A, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2014;15(7):689–699. doi:10.1016/S1470-2045(14)70178-0
- Kuramochi M, Fukuhara H, Nobukuni T, et al. TSLC1 is a tumorsuppressor gene in human non-small-cell lung cancer. *Nat Genet*. 2001;27(4):427–430. doi:10.1038/86934
- Goto A, Niki T, Chi-Pin L, et al. Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. *Cancer Sci.* 2005;96(8):480–486. doi:10.1111/j.1349-7006.2005.00075.x

- Takahashi Y, Iwai M, Kawai T, et al. A preview expression of tumor suppressors CADM and 4.1P an invasive essions of primary breast cancer. *Breast Cances*, 8204, 19(3):242-152. doi:10.1007/s12282-011-0272-7
- 7. Wikman and estphal L, Schold bet al. Loss of CADM1 expression is astronated with poor progressis and brain metastasis in breast cancer patients. *cotarget*. 2014;5(10):3076–3087. doi:10.18632/ userget.1832
  - Saito M, Goto A, Abe N, et al. Decreased expression of CADM1 and CADM4 are associated with advanced stage breast cancer. *Oncol Lett.* 2018;112):2401–2406. doi:10.3892/ol.2017.7536
  - Shukla GC singh J, Barik S. MicroRNAs: processing, Maturation, the ognition and Regulatory Functions. *Mol Cell Pharmacol*. 2011;3(3):83–92.
- tel DP. MicroRNAs: target recognition and regulatory functions. *Cell*. 2009;136(2):215–233. doi:10.1016/j.cell.2009.01.002
- Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res.* 2009;19(1):92–105. doi:10.1101/gr.082701.108
- Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714. doi:10.1038/nrg2634
- Chernyy V, Pustylnyak V, Kozlov V, Gulyaeva L. Increased expression of miR-155 and miR-222 is associated with lymph node positive status. *J Cancer*. 2018;9(1):135–140. doi:10.7150/jca.22181
- 14. Zheng SR, Guo GL, Zhang W, et al. Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. *Oncol Rep.* 2012;27(4):1149–1155. doi:10.3892/or.2012.1634
- Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83(4):803–819. doi:10.1016/ S0039-6109(03)00034-3
- 16. Zhu Z, Teng Z, van Duijnhoven FJB, et al. Interactions between RASA2, CADM1, HIF1AN gene polymorphisms and body fatness with breast cancer: a population-based case-control study in China. *Oncotarget.* 2017;8(58):98258–98269. doi:10.18632/oncotarget.21530
- 17. Sun Z, Meng C, Wang S, et al. MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma. *BMC Cancer.* 2014;14:616.
- Li QJ, Zhou L, Yang F, et al. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. *Tumour Biol.* 2012;33(5):1455–1465. doi:10.1007/s13277-012-0396-1
- Zheng G, Li N, Jia X, et al. MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer. J Mol Med (Berl). 2016;94(10):1129–1141. doi:10.1007/s00109-016-1417-0

- 20. Ishimura M, Sakuraiyageta M, Maruyama T, et al. Involvement of miR-214 and miR-375 in Malignant Features of Non-Small-Cell Lung Cancer by Down-Regulating CADM1. *J Cancer Ther.* 2012;3 (4):379–387.
- Arslan UY, Oksuzoglu B, Aksoy S, et al. Breast cancer subtypes and outcomes of central nervous system metastases. *Breast.* 2011;20 (6):562–567. doi:10.1016/j.breast.2011.07.017
- 22. Harrell JC, Prat A, Parker JS, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. *Breast Cancer Res Treat.* 2012;132(2):523–535. doi:10.1007/s10549-011-1619-7
- Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. *Cancer Epidemiol Biomarkers Prev.* 2012;21(8):1236–1243.
- 24. Wang J, Wu J. Role of miR-155 in breast cancer. Front Biosci (Landmark Ed). 2012;17:2350-2355.

- 25. Zuo J, Yu Y, Zhu M, et al. Inhibition of miR-155, a therapeutic target for breast cancer, prevented in cancer stem cell formation. *Cancer Biomark*. 2018;21(2):383–392. doi:10.3233/CBM-170642
- 26. Wang Q, Li C, Zhu Z, et al. miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells. *Anticancer Drugs*. 2016;27(1):9–16. doi:10.1097/CAD.00000000 00000296
- 27. Nakahata S, Morishita K. CADM1/TSLC1 is a novel cell surface marker for adult T-cell leukemia/lymphoma. *J Clin Exp Hematop*. 2012;52(1):17–22.
- Liang QL, Chen GQ, Li ZY, Wang BR. Function and histopathology of a cell adhesion molecule TSLC1 in cancer. *Cancer Invest.* 2011;29 (2):107–112.
- 29. Yu DD, Lv MM, Chen WX, et al. Role of miR-155 in drug resistance of breast cancer. *Tumour Biol.* 2015;36(3):1205-1401. doi:10.1007/ s13277-015-3263-z

**OncoTargets and Therapy** 

#### **Dove**press

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.